Thomas G Wiggans - Net Worth and Insider Trading

Thomas G Wiggans Net Worth

The estimated net worth of Thomas G Wiggans is at least $5 Million dollars as of 2024-11-05. Thomas G Wiggans is the CEO & Chairman of the Board of Dermira Inc and owns about 256,925 shares of Dermira Inc (DERM) stock worth over $5 Million. Thomas G Wiggans is the Director of Jasper Therapeutics Inc and owns about 5,000 shares of Jasper Therapeutics Inc (JSPR) stock worth over $112,450. Thomas G Wiggans is also the CEO of Pardes Biosciences Inc and owns about 50,000 shares of Pardes Biosciences Inc (PRDS) stock worth over $108,000. Details can be seen in Thomas G Wiggans's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas G Wiggans has not made any transactions after 2023-11-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Thomas G Wiggans

Thomas G Wiggans Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Thomas G Wiggans owns 7 companies in total, including Forma Therapeutics Holdings Inc (FMTX) , Annexon Inc (ANNX) , and Dermira Inc (DERM) among others .

Click here to see the complete history of Thomas G Wiggans’s form 4 insider trades.

Insider Ownership Summary of Thomas G Wiggans

Ticker	Comapny	Transaction Date	Type of Owner
FMTX	Forma Therapeutics Holdings Inc	2020-09-07	director
ANNX	Annexon Inc	2020-07-23	director
DERM	Dermira Inc	2020-02-20	director & CEO & Chairman of the Board
		2008-06-04	director
		2022-01-25	director
		2022-12-05	director & Chief Executive Officer
		2023-11-28	director

Thomas G Wiggans Latest Holdings Summary

Thomas G Wiggans currently owns a total of 3 stocks. Among these stocks, Thomas G Wiggans owns 256,925 shares of Dermira Inc (DERM) as of August 19, 2019, with a value of $5 Million and a weighting of 95.62%. Thomas G Wiggans owns 5,000 shares of Jasper Therapeutics Inc (JSPR) as of November 28, 2023, with a value of $112,450 and a weighting of 2.23%. Thomas G Wiggans also owns 50,000 shares of Pardes Biosciences Inc (PRDS) as of December 5, 2022, with a value of $108,000 and a weighting of 2.14%.

Latest Holdings of Thomas G Wiggans

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
DERM	Dermira Inc	2019-08-19	256,925	18.75	4,817,344
JSPR	Jasper Therapeutics Inc	2023-11-28	5,000	22.49	112,450
PRDS	Pardes Biosciences Inc	2022-12-05	50,000	2.16	108,000

Holding Weightings of Thomas G Wiggans

Thomas G Wiggans Form 4 Trading Tracker

According to the SEC Form 4 filings, Thomas G Wiggans has made a total of 0 transactions in Dermira Inc (DERM) over the past 5 years. The most-recent trade in Dermira Inc is the acquisition of 23,419 shares on August 19, 2019, which cost Thomas G Wiggans around $199,998.

According to the SEC Form 4 filings, Thomas G Wiggans has made a total of 3 transactions in Jasper Therapeutics Inc (JSPR) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Jasper Therapeutics Inc is the acquisition of 1,000 shares on November 28, 2023, which cost Thomas G Wiggans around $6,500.

According to the SEC Form 4 filings, Thomas G Wiggans has made a total of 2 transactions in Pardes Biosciences Inc (PRDS) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Pardes Biosciences Inc is the acquisition of 12,500 shares on December 5, 2022, which cost Thomas G Wiggans around $13,625.

Insider Trading History of Thomas G Wiggans

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Thomas G Wiggans Trading Performance

GuruFocus tracks the stock performance after each of Thomas G Wiggans's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas G Wiggans is 73.92%. GuruFocus also compares Thomas G Wiggans's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas G Wiggans within 3 months outperforms 8 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Thomas G Wiggans's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Thomas G Wiggans

Average Return

Average return per transaction

Outperforming Transactions

1 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	12.65
Relative Return to S&P 500(%)	10.88

Thomas G Wiggans Ownership Network

Ownership Network List of Thomas G Wiggans

No Data

Ownership Network Relation of Thomas G Wiggans

Thomas G Wiggans Owned Company Details

What does Forma Therapeutics Holdings Inc do?

Who are the key executives at Forma Therapeutics Holdings Inc?

Thomas G Wiggans is the director of Forma Therapeutics Holdings Inc. Other key executives at Forma Therapeutics Holdings Inc include EVP & Research & Development Agustin Melian , SVP & Chief Scientific Officer David N Cook , and SVP & Chief Financial Officer Todd Shegog .

Forma Therapeutics Holdings Inc (FMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forma Therapeutics Holdings Inc (FMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forma Therapeutics Holdings Inc (FMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forma Therapeutics Holdings Inc (FMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forma Therapeutics Holdings Inc Insider Transactions

No Available Data

What does Annexon Inc do?

Who are the key executives at Annexon Inc?

Thomas G Wiggans is the director of Annexon Inc. Other key executives at Annexon Inc include EVP & Chief Innovation Officer Ted Yednock , EVP & Chief Business Officer Michael Overdorf , and EVP & Chief Financial Officer Jennifer Lew .

Annexon Inc (ANNX) Insider Trades Summary

Over the past 18 months, Thomas G Wiggans made no insider transaction in Annexon Inc (ANNX). Other recent insider transactions involving Annexon Inc (ANNX) include a net sale of 74,985 shares made by Ted Yednock , a net purchase of 22,400 shares made by William H. Carson , and a net sale of 6,563 shares made by Jennifer Lew .

In summary, during the past 3 months, insiders sold 26,408 shares of Annexon Inc (ANNX) in total and bought 6,400 shares, with a net sale of 20,008 shares. During the past 18 months, 92,392 shares of Annexon Inc (ANNX) were sold and 672,400 shares were bought by its insiders, resulting in a net purchase of 580,008 shares.

Annexon Inc (ANNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Annexon Inc Insider Transactions

No Available Data

What does Dermira Inc do?

Who are the key executives at Dermira Inc?

Thomas G Wiggans is the director & CEO & Chairman of the Board of Dermira Inc. Other key executives at Dermira Inc include CFO Andrew Guggenhime , Chief Commercial Officer Lori Lyons-williams , and 10 percent owner Lilly Eli & Co .

Dermira Inc (DERM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dermira Inc (DERM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dermira Inc (DERM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dermira Inc (DERM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dermira Inc Insider Transactions

No Available Data

What does Sangamo Therapeutics Inc do?

Who are the key executives at Sangamo Therapeutics Inc?

Thomas G Wiggans is the director of Sangamo Therapeutics Inc. Other key executives at Sangamo Therapeutics Inc include 10 percent owner Biogen Inc. , SVP-Chief Development Officer Nathalie Dubois-stringfellow , and 10 percent owner Biogen Ma Inc. .

Sangamo Therapeutics Inc (SGMO) Insider Trades Summary

Over the past 18 months, Thomas G Wiggans made no insider transaction in Sangamo Therapeutics Inc (SGMO). Other recent insider transactions involving Sangamo Therapeutics Inc (SGMO) include a net sale of 6,000,000 shares made by Biogen Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Sangamo Therapeutics Inc (SGMO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 6,000,000 shares of Sangamo Therapeutics Inc (SGMO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 6,000,000 shares.

Sangamo Therapeutics Inc (SGMO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sangamo Therapeutics Inc Insider Transactions

No Available Data

What does CymaBay Therapeutics Inc do?

Who are the key executives at CymaBay Therapeutics Inc?

Thomas G Wiggans is the director of CymaBay Therapeutics Inc. Other key executives at CymaBay Therapeutics Inc include Chief Scientific Officer Charles Mcwherter , Vice President & Finance Daniel Menold , and General Counsel Paul T Quinlan .

CymaBay Therapeutics Inc (CBAY) Insider Trades Summary

Over the past 18 months, Thomas G Wiggans made no insider transaction in CymaBay Therapeutics Inc (CBAY). Other recent insider transactions involving CymaBay Therapeutics Inc (CBAY) include a net sale of 171,559 shares made by Charles Mcwherter , a net sale of 93,000 shares made by Paul T Quinlan , and a net sale of 52,442 shares made by Daniel Menold .

In summary, during the past 3 months, insiders sold 0 shares of CymaBay Therapeutics Inc (CBAY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 481,646 shares of CymaBay Therapeutics Inc (CBAY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 481,646 shares.

CymaBay Therapeutics Inc (CBAY)'s detailed insider trading history can be found in Insider Trading Tracker table.

CymaBay Therapeutics Inc Insider Transactions

No Available Data

What does Pardes Biosciences Inc do?

Who are the key executives at Pardes Biosciences Inc?

Thomas G Wiggans is the director & Chief Executive Officer of Pardes Biosciences Inc. Other key executives at Pardes Biosciences Inc include 10 percent owner Fs Development Holdings Ii, Llc , 10 percent owner Foresite Capital Fund V, L.p. , and 10 percent owner Foresite Capital Opportunity Fund V, L.p. .

Pardes Biosciences Inc (PRDS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Pardes Biosciences Inc (PRDS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pardes Biosciences Inc (PRDS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Pardes Biosciences Inc (PRDS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pardes Biosciences Inc Insider Transactions

No Available Data

What does Jasper Therapeutics Inc do?

Who are the key executives at Jasper Therapeutics Inc?

Thomas G Wiggans is the director of Jasper Therapeutics Inc. Other key executives at Jasper Therapeutics Inc include Chief Operating Officer Jeetinder Singh Mahal , 10 percent owner Carlyle Group Inc. , and other: See Footnote 1 Velan Capital Master Fund Lp .

Jasper Therapeutics Inc (JSPR) Insider Trades Summary

Over the past 18 months, Thomas G Wiggans made 3 insider transaction in Jasper Therapeutics Inc (JSPR) with a net purchase of 50,000. Other recent insider transactions involving Jasper Therapeutics Inc (JSPR) include a net sale of 11,700 shares made by Jeetinder Singh Mahal , a net purchase of 350,000 shares made by Velan Capital Master Fund Lp , and a net purchase of 190,000 shares made by Carlyle Group Inc. .

In summary, during the past 3 months, insiders sold 900 shares of Jasper Therapeutics Inc (JSPR) in total and bought 0 shares, with a net sale of 900 shares. During the past 18 months, 4,397 shares of Jasper Therapeutics Inc (JSPR) were sold and 545,000 shares were bought by its insiders, resulting in a net purchase of 540,604 shares.

Jasper Therapeutics Inc (JSPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Jasper Therapeutics Inc Insider Transactions

No Available Data

Thomas G Wiggans Mailing Address

Above is the net worth, insider trading, and ownership report for Thomas G Wiggans. Currently GuruFocus does not have mailing address information for Thomas G Wiggans.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.